Joseph Shulman
Chief Tech/Sci/R&D Officer at RHYTHM PHARMACEUTICALS, INC.
Net worth: 1 300 $ as of 2024-03-30
Profile
Joseph Shulman's current job is Chief Technical Officer at Rhythm Pharmaceuticals, Inc. His former jobs include Senior Vice President-Technical Operations at Ra Pharmaceuticals, Inc. and Senior Vice President-Global Technical Operations at Novelion Therapeutics, Inc. He holds an MBA from Boston University and an undergraduate degree from the University of Miami.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-20 | 30 ( 0.00% ) | 1 300 $ | 2024-03-30 |
Joseph Shulman active positions
| Companies | Position | Start |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-07-26 |
Former positions of Joseph Shulman
| Companies | Position | End |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-06-30 |
| NOVELION THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2019-06-30 |
Training of Joseph Shulman
| Boston University | Masters Business Admin |
| University of Miami | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Joseph Shulman
